Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644884
Effects of Deltoid Strengthening Exercises in Patients With Adhesive CapsulitisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07644884Not Yet Recruiting
Not Applicable
Effects of Deltoid Strengthening Exercises in Patients With Adhesive CapsulitisRiphah International Univ...
NCT07645833
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/SNot Yet RecruitingPhase 3
NCT07645833Not Yet Recruiting
Phase 3
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/S
NCT07646509
An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom DisorderUniversity of ViennaRecruitingNot Applicable
NCT07646509Recruiting
Not Applicable
An Ecological Momentary Intervention for the Reduction of Impairment in Somatic...University of Vienna
NCT07644377
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary AngioplastyAssistance Publique - Hôpitaux de ParisNot Yet RecruitingPhase 3
NCT07644377Not Yet Recruiting
Phase 3
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboe...Assistance Publique - Hôp...
NCT07646405
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endurance in the Geriatric PopulationRiphah International UniversityRecruitingNot Applicable
NCT07646405Recruiting
Not Applicable
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endura...Riphah International Univ...
NCT07645144
FES-assisted Gait Training for Incomplete Spinal Cord InjuryStichting ReadeEnrolling By InvitationNot Applicable
NCT07645144Enrolling By Invitation
Not Applicable
FES-assisted Gait Training for Incomplete Spinal Cord InjuryStichting Reade
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07646197
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver DiseaseHenry Ford Health SystemRecruitingNot Applicable
NCT07646197Recruiting
Not Applicable
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Di...Henry Ford Health System
NCT07644936
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisNot Yet Recruiting
NCT07644936Not Yet Recruiting
—
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Speci...
NCT07644416
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana UniversityNot Yet RecruitingNot Applicable
NCT07644416Not Yet Recruiting
Not Applicable
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana University
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07645014
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polycystic Ovarian Syndrome.Riphah International UniversityRecruitingNot Applicable
NCT07645014Recruiting
Not Applicable
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polyc...Riphah International Univ...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644780
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Maternal Multiple Micronutrients SupplementsNutrition InternationalCompletedNot Applicable
NCT07644780Completed
Not Applicable
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Mater...Nutrition International
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07646093
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in ChildrenHospital Universitario de CaracasCompletedNot Applicable
NCT07646093Completed
Not Applicable
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillect...Hospital Universitario de...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting7 (35%)
Completed2 (10%)
Enrolling by invitation1 (5%)
not_applicable10 (50%)
Not Specified5 (25%)
Phase 33 (15%)
Phase 22 (10%)